Showing results (101-110 of 384) with videos related to

Sort By:
Pageof 39
BJU International|March 26, 2014
Twitter response to the United States Preventive Services Task Force recommendations against screening with prostate-specific antigenVinay Prabhu, Ted Lee, Stacy Loeb, et al.
The Journal of Urology|April 23, 2019
External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate CancerTimothy J Daskivich, I-Chun Thomas, Michael Luu, et al.
Implementation Science : IS|September 4, 2016
A qualitative study to understand guideline-discordant use of imaging to stage incident prostate cancerDanil V Makarov, Erica Sedlander, R Scott Braithwaite, et al.
Human Pathology|August 31, 2002
Should the diagnosis of benign prostatic hyperplasia be made on prostate needle biopsy?Michael P Viglione, Stephen Potter, Alan W Partin, et al.
BJU International|April 8, 2018
Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefitMohit Gupta, Hiten D Patel, Zeyad R Schwen, et al.
The Journal of Urology|September 6, 2006
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortalityStephen J Freedland, Elizabeth B Humphreys, Leslie A Mangold, et al.
The Journal of Urology|March 20, 2012
Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancerJeffrey K Mullins, Misop Han, Phillip M Pierorazio, et al.
The Prostate|July 13, 2010
Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomyRobert W Veltri, Sumit Isharwal, M Craig Miller, et al.
Urology|July 3, 2003
Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003Masood A Khan, Misop Han, Alan W Partin, et al.
BJU International|June 26, 2004
Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSAJ Kellogg Parsons, Michael K Brawer, Carol D Cheli, et al.
Pageof 39